2026-04-17T03:25:37Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/104092025-10-24T08:55:38Zcom_2072_378070com_2072_378040com_2072_378071col_2072_378092col_2072_378097

2025-10-24T08:55:38Z urn:hdl:11351/10409 Influenza Vaccine Effectiveness against Hospitalization, Season 2021/22: A Test-Negative Design Study in Barcelona Fornaguera, Mar CARBONES FARGAS, INGRID Armadans, Lluis Tejada, Gabriela Guananga, David Vivet Escalé, Martí Peñalver-Piñol, Arnau del Oso, Arnau Martínez-Gómez, Xavier Parés-Badell, Oleguer Rodrigo Pendás, José Ángel BORRAS BERMEJO, BLANCA Torrecilla Martínez, Irene Otero-Romero, Susana Antón Pagarolas, Andrés Andrés Vergés, Cristina Grip - Prevenció Vacunes antigripals Hospitals - Pacients Medicaments - Eficàcia DISEASES::Virus Diseases::RNA Virus Infections::Orthomyxoviridae Infections::Influenza, Human Other subheadings::Other subheadings::Other subheadings::/prevention & control CHEMICALS AND DRUGS::Complex Mixtures::Biological Products::Vaccines::Viral Vaccines::Influenza Vaccines ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Patient Care::Hospitalization PUBLIC HEALTH::Epidemiology and Biostatistics::Epidemiology::Uses of Epidemiology::Effectiveness ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Orthomyxoviridae::gripe humana Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::productos biológicos::vacunas::vacunas víricas::vacunas de la gripe TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::asistencia al paciente::hospitalización SALUD PÚBLICA::epidemiología y bioestadística::epidemiología::usos de la epidemiología::efectividad Effectiveness; Hospitalization; Influenza Efectivitat; Hospitalització; Grip Efectividad; Hospitalización; Gripe Background: Vaccination is considered the most effective measure for preventing influenza and its complications. The influenza vaccine effectiveness (IVE) varies annually due to the evolution of influenza viruses and the update of vaccine composition. Assessing the IVE is crucial to facilitate decision making in public health policies. Aim: to estimate the IVE against hospitalization and its determinants in the 2021/22 season in a Spanish tertiary hospital. Methods: We conducted a prospective observational test-negative design study within the Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project. Hospitalized patients with severe acute respiratory infection (SARI) and an available influenza reverse transcription polymerase chain reaction (RT-PCR) were selected and classified as cases (positive influenza RT-PCR) or controls (negative influenza RT-PCR). Vaccine information was obtained from electronic clinical records shared by public healthcare providers. Information about potential confounders was obtained from hospital clinical registries. The IVE was calculated by subtracting the ratio of the odds of vaccination in cases and controls from one, as a percentage (IVE = (1 − odds ratio (OR)) × 100). Multivariate IVE estimates were calculated using logistic regression. Results: In total, 260 severe acute respiratory infections (SARI) were identified, of which 34 were positive for influenza, and all were subtype A(H3N2). Fifty-three percent were vaccinated. Adjusted IVE against hospitalization was 26.4% (95% CI −69% to 112%). IVE determinants could not be explored due to sample size limitations. Conclusion: Our data revealed non-significant moderate vaccine effectiveness against hospitalization for the 2021/2022 season. This study has been funded by the DRIVE IMI project. The DRIVE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No. 777363); this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the EFPIA. 2025-10-24T08:55:38Z 2025-10-24T08:55:38Z 2023-10-05T12:19:52Z 2023-10-05T12:19:52Z 2023-09-02 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/10409 Vaccines;11(9) https://doi.org/10.3390/vaccines11091450 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess MDPI Scientia